©2024 Stanford Medicine
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Recruiting
I'm InterestedTrial ID: NCT00931632
Purpose
This phase 3, multi-center, double blind, placebo-controlled, randomized clinical trial will
attempt to demonstrate if preterm infants who require mechanical ventilation and/or positive
pressure support at any point during days 5 to 14 after birth may benefit from treatment with
iNO.
Official Title
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Eligibility
Inclusion Criteria:
- Preterm infants who are:
1. 500 to 1250 grams at birth
2. < 30 weeks gestational age
3. 5 to 14 days of age (inclusive) at the time of entry
4. Requiring mechanical ventilation or for those infants ≤ 800 grams, positive
pressure support (including CPAP) for respiratory insufficiency on days 5 to 14
days of age (inclusive)
Exclusion Criteria:
1. Preterm infants with life-threatening anomalies (cranial, cardiac, thoracic,
chromosomal) or congenital diaphragmatic hernia with lung hypoplasia, or any subject
who will not receive complete intensive care
2. Preterm infants with bilateral Grade 4 intraventricular hemorrhage (IVH)
3. Subjects who are dependent on right to left shunting to maintain the systemic
circulation
4. Preterm infants who received prior iNO therapy
5. Use of another investigational agent
Intervention(s):
drug: inhaled nitric oxide
drug: Placebo
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
M. Bethany Ball
6507258342